Exencial Wealth Advisors LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 42,898 shares of the company’s stock after buying an additional 2,025 shares during the period. Exencial Wealth Advisors LLC’s holdings in Zoetis were worth $2,735,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its stake in Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the last quarter. Harfst & Associates Inc. lifted its stake in Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in Zoetis during the second quarter worth about $119,000. Peddock Capital Advisors LLC bought a new stake in Zoetis during the second quarter worth about $140,000. Finally, Shine Investment Advisory Services Inc. lifted its stake in Zoetis by 86.5% during the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock worth $143,000 after purchasing an additional 1,040 shares during the last quarter. 93.37% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have issued reports on the company. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research note on Thursday, October 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 price target on shares of Zoetis in a research note on Wednesday, September 6th. BidaskClub lowered Zoetis from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Morgan Stanley lifted their price target on Zoetis from $61.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $62.00 price target on shares of Zoetis in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $67.65.
COPYRIGHT VIOLATION NOTICE: “Zoetis Inc. (ZTS) Shares Bought by Exencial Wealth Advisors LLC” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/11/20/zoetis-inc-zts-shares-bought-by-exencial-wealth-advisors-llc.html.
Shares of Zoetis Inc. (NYSE:ZTS) traded up $0.38 during trading hours on Monday, reaching $70.79. The company had a trading volume of 2,355,100 shares, compared to its average volume of 2,806,257. Zoetis Inc. has a 52 week low of $48.55 and a 52 week high of $71.12. The stock has a market cap of $34,490.00, a P/E ratio of 32.47, a PEG ratio of 2.07 and a beta of 1.02. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the previous year, the business earned $0.52 EPS. Zoetis’s revenue was up 8.5% compared to the same quarter last year. equities research analysts anticipate that Zoetis Inc. will post 2.37 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be issued a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a yield of 0.59%. Zoetis’s dividend payout ratio is presently 22.11%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.